Neoadjuvant Immunotherapy SCLC Treatment Results
- Neoadjuvant immunotherapy plus chemotherapy appears to be effective in patients with limited-stage small cell lung cancer (LS-SCLC), a new report indicates.
- SCLC makes up only about 10-15% of lung cancer cases, the authors explained.
- PD-1 inhibitors have shown considerable promise for patients with extensive-stage SCLC.
“`html
Neoadjuvant Immunotherapy Shows Promise in Limited-Stage Small Cell Lung Cancer
Neoadjuvant immunotherapy plus chemotherapy appears to be effective in patients with limited-stage small cell lung cancer (LS-SCLC), a new report indicates. The study was published in Thoracic Cancer.1
SCLC makes up only about 10-15% of lung cancer cases, the authors explained. Limited-stage cases of SCLC (LS-SCLC) make up a minority of new SCLC cases, they noted, as most patients are not diagnosed until their disease has reached extensive-stage status.
PD-1 inhibitors have shown considerable promise for patients with extensive-stage SCLC. And just last year, the ADRIATIC study (Nct03703297) suggested that the anti-PD-1 therapy durvalumab (Imfinzi; AstraZeneca) was effective as a consolidation therapy for patients with stable LS-SCLC post-concurrent chemoradiotherapy,the investigators noted.2 That study was an important milestone demonstrating the efficacy of PD-1/PD-L1 inhibitors in a LS-SCLC setting, they explained.1
In the new report, the investigators wanted to expand the knowledge base around the role of neoadjuvant immunotherapy in treating patients with LS-SCLC. To do so, they searched for existing research that included clinical outcomes and safety data for the treatment regimen. After exclusions, they analyzed a